Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Research Alliance III to merge with Oak Hill Bio

PRIVATEJul 27, 2026•14 days ago

Acquiring Company

Research Alliance Corporation III

Acquired Company

Oak Hill Bio

United StatesCambridgeBiotechnologyHealth CareBiotechnologyHealth CareTherapeutics

Description

Research Alliance Corporation III and Oak Hill Bio have announced a definitive business combination agreement. The merger is expected to close by the end of 2026 and will facilitate significant funding for Oak Hill Bio's development of rugonersen for Angelman syndrome. The combined entity will be renamed Oak Hill Bio, Inc. and will trade on the Nasdaq under the symbol 'OAKH'.

Company Information

Company

Research Alliance Corporation III

Location

United States

About

Research Alliance Corporation III operates as a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, or other similar business combination with one or more businesses. The company is focused on acquiring operations in the biotechnology and technology sectors, emphasizing companies involved in the development and commercialization of innovative healthcare solutions. Located in New York, NY, its strategic interest lies in emerging growth companies that exhibit strong potential for growth and profitability. As an emerging growth company, Research Alliance Corporation III also avails itself of certain regulatory reliefs aimed at facilitating its public offering and future operations.

Predictive Intelligence
Strategic

ML-powered predictions for Research Alliance Corporation III's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Oak Hill Bio?

Oak Hill Bio was acquired by Research Alliance Corporation III, based in United States. The deal was reported on July 27, 2026. Research Alliance Corporation III is privately held and operates in Biotechnology.

When did Research Alliance Corporation III acquire Oak Hill Bio?

Research Alliance Corporation III's acquisition of Oak Hill Bio was reported on July 27, 2026. Research Alliance Corporation III and Oak Hill Bio have announced a definitive business combination agreement. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Oak Hill Bio do?

Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. It is privately held, operating in Biotechnology, and is based in Cambridge.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.